Umekage Masafumi, Sato Yoshiko, Takasu Naoko
Department of Fundamental Cell Technology, Center of iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507 Japan.
Inflamm Regen. 2019 Sep 2;39:17. doi: 10.1186/s41232-019-0106-0. eCollection 2019.
Induced pluripotent stem cells (iPSCs) can be produced from various somatic cells and have the ability to differentiate into various cells and tissues of the body. Regenerative medicine using iPSCs is expected to manage diseases lacking effective treatments at present. We are establishing a safe and effective iPSC stock that can be used for regenerative medicine. Our iPSC stock is recruited from healthy, consenting HLA-type homozygous donors and is made with peripheral blood-derived mononuclear cells or umbilical cord blood. We hope to minimize the influence of immune rejection by preparing HLA homozygous iPSCs. Our stock is made at the Cell Processing Center (CPC), Center for iPS Cell Research and Application (CiRA). We are preparing iPS cells that maximize matching of the Japanese population at the major HLA loci. This iPSC stock is intended to be offered not only to Japanese centers but also overseas medical institutions and companies. In August 2015, we began offering the iPSC stock for regenerative medicine and now offer 21 clones made from 5 donors.
诱导多能干细胞（iPSC）可从多种体细胞产生，具有分化为身体各种细胞和组织的能力。利用iPSC的再生医学有望治疗目前缺乏有效治疗方法的疾病。我们正在建立一种可用于再生医学的安全有效的iPSC库。我们的iPSC库招募自健康且同意捐献的HLA型纯合供体，由外周血来源的单核细胞或脐带血制成。我们希望通过制备HLA纯合iPSC来尽量减少免疫排斥的影响。我们的细胞库在iPS细胞研究与应用中心（CiRA）的细胞处理中心（CPC）制备。我们正在制备在主要HLA位点与日本人群匹配度最高的iPS细胞。这种iPSC库不仅打算提供给日本的中心，也提供给海外医疗机构和公司。2015年8月，我们开始提供用于再生医学的iPSC库，目前提供由5名供体制备的21个克隆细胞系。
